NEW YORK (TheStreet) -- Hyperion Therapeutics (HPTX) is a rare-disease drug developer with an FDA approval decision for Ravicti expected on Jan. 23, 2013. Ravicti is being developed to treat adults and children with urea cycle disorders (UCD) -- a genetic disease that prevents enzymes from removing ammonia in the blood.
As I've written previously, FDA drug approval decisions are prime biotech run-up trading opportunities. Hyperion will be no exception due to its low float (16 million shares outstanding), small short interest and low daily average trading volume. In many ways, I see Hyperion acting similarly to Supernus Pharma (SUPN) during its first tentative FDA approval.
Hyperion closed Tuesday at $10.54. Once the looming Ravicti approval decision lands on traders' radar screens, the stock could move into the $12-13 per share range ahead of the FDA's Jan. 23 decision, with a spike as high as $15-17 if Ravicti is approved.
I believe FDA will approve Ravicti. The drug is a reformulation of Buphenyl, currently the only product used to control ammonia levels in UCD patients. Ravicti, however, is more tolerable and convenient than Buphenyl while retaining equivalent efficacy, according to clinical data filed in support of the drug's approval.In September, Hyperion announced a three-month delay in Ravicti's FDA approval decision, necessitated by the agency's requirement for additional time to review data that support the use of the drug in children with UCD. I don't see this delay as a risk to FDA's decision to approve Ravicti. Hyperion completed an initial public offering in July, selling 5.75 million shares at $10. As of September 30, the company reported $56.5 million in cash and $12 million in debt. Hyperion's quarterly burn rate is approximately $7 million. That's a good cash position, bolstering Hyperion's run-up potential into the Ravicti approval decision just two months away. Disclosure: Messier is long Hyperion.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV